Psoriatic Arthritis Treatment

Global Psoriatic Arthritis Treatment Market to Reach US$16.3 Billion by 2030

The global market for Psoriatic Arthritis Treatment estimated at US$10.8 Billion in the year 2024, is expected to reach US$16.3 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$9.5 Billion by the end of the analysis period. Growth in the Non-biologics segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 11.0% CAGR

The Psoriatic Arthritis Treatment market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global "Psoriatic Arthritis Treatment" Market – Is the Era of Personalized Autoimmune Care Here?

Is Rising Disease Awareness Catalyzing Early Diagnosis and Treatment?
Psoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, is gaining recognition due to rising public and clinical awareness. Previously underdiagnosed or misdiagnosed, PsA is now being identified earlier, leading to timely therapeutic intervention and better outcomes. Increased awareness campaigns by healthcare organizations, dermatology clinics, and rheumatology societies are encouraging patients to report early joint discomfort or stiffness. Innovations in imaging and biomarker testing are enhancing diagnostic accuracy, while patient support communities are driving proactive care-seeking behavior. These factors are boosting early-stage treatment initiation, a crucial determinant of disease progression and quality of life.

Are Biologic and Targeted Therapies Transforming the Treatment Landscape?
The PsA treatment market has undergone a dramatic shift with the advent of biologics and small molecule inhibitors. TNF inhibitors, IL-17 and IL-23 inhibitors, and JAK inhibitors have emerged as frontline therapies, offering more targeted immunomodulation with improved efficacy and reduced systemic side effects. As biologics become more affordable and biosimilars enter the market, access is expanding across different geographies. Additionally, oral therapies such as PDE4 inhibitors are providing more convenient options for patients unwilling or unable to use injectable biologics. Clinical guidelines are increasingly supporting early biologic use to prevent joint damage, further pushing demand for advanced therapies.

Is Patient-Centered Care Driving Treatment Customization?
Psoriatic arthritis manifests differently among patients, making personalized treatment strategies critical. Shared decision-making is gaining traction in rheumatology practices, with patients and providers working together to select therapies based on comorbidities, lifestyle preferences, and treatment goals. Digital health tools are helping track symptoms, adherence, and response to medication, enabling real-time adjustments to care plans. Patients are also more educated about potential side effects, access programs, and alternative treatment options. This shift toward individualized therapy and improved access support services is enhancing treatment satisfaction and persistence, reinforcing demand for diverse therapeutic offerings.

The Growth in the Psoriatic Arthritis Treatment Market Is Driven by Several Factors…
The growth in the psoriatic arthritis treatment market is driven by several factors including therapeutic innovation, broader diagnosis, and changing patient engagement dynamics. Technologically, the development of new biologic pathways and oral agents is expanding treatment options with higher efficacy and specificity. End-use growth is observed in rheumatology clinics and specialty pharmacies that provide coordinated care and insurance navigation. Consumer trends are shifting toward informed, proactive disease management with greater use of digital health tools and participation in clinical trials. Further, increasing pharmaceutical investments in autoimmune drug pipelines, rising prevalence in developed markets, and stronger reimbursement frameworks are reinforcing the expansion of PsA treatment offerings worldwide.

SCOPE OF STUDY:

The report analyzes the Psoriatic Arthritis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Biologics, Non-biologics, Combination Therapy); Product Type (Prescription & Over-the-Counter); Administration Route (Parenteral, Oral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• AbbVie Inc.
• Alvotech
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Celltrion, Inc.
• Currax Pharmaceuticals LLC
• Eli Lilly and Company
• Janssen Pharmaceuticals (Johnson & Johnson)
• Merck & Co., Inc.
• MoonLake Immunotherapeutics
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB S.A.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.